Using CBD to Treat Schizophrenia
GW Pharmaceuticals – a UK based biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform – recently announced that it has started Phase 2 clinical trials on a potential drug for the treatment of schizophrenia made from the marijuana compound cannabidiol (CBD).
How Might Cannabidiol Impact Schizophrenia?
Cannabidiol (CBD) is a compound that has shown possible benefits in studies on a variety of animal models of mental health, including anxiety, bipo...
Just What Does Marijuana Do Inside Your Body?
Raphael Mechoulam, the man who first synthesized THC, the main ingredient in marijuana, and is often referred to as the “father of marijuana resear...
CBD and Schizophrenia
Some research has been conducted on the use of CBD to help treat schizophrenia. A study conducted in 2012 suggests that CBD was able to moderately prevent the endocannabinoid, anandamide, from degrading. When anandamide levels are elevated in cerebrospinal fluid, they correlate inversely to the psychotic symptoms of schizophrenia, meaning the symptoms are lessened or in some cases absent.
Get Involved: CBD Clinical Trials
Research into the effects of cannabinoids, including cannabidiol, continues to progress into exploring an astonishing variety of systems and disorders. Although government restrictions on cannabis research hindered advancement until very recently, currently research has been blooming. If you would like to take part in this research and further our understanding of the biological mechanisms underlying the relief provided by the endocannabinoid system - check out the current clinical trials involving CBD. Many are currently recruiting participants all across the country - you could get involved!